ClinicalTrials.gg
Not yet recruitingNCT07943741KeTADiDUpdated Nov 17, 2026

Ketamine for Treatment of Alzheimers Disease Related Depression

A Phase 2 interventional study of Ketamine and saline and Active Placebo (Midazolam) Infusion in Late Life Depression (LLD), MCI and MCI-AD, Early Stage Alzheimer's Disease, sponsored by Vanderbilt University Medical Center. Not yet recruiting at 1 site in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Vanderbilt University Medical Center · Phase 2, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 319 studies in Depressive Disorder with a site in United States — 39 open to participants now, 45 under way, 2 of them phase 3. Depressive Disorder · United States.

Planned enrollment
209th of 275
30 · median 85
Started
2026
with 10 others
Phase 2
49 of 319
8 open now
Primary completion
2029-12
later than 39 of 44 live
Registered
319th of 319
by date

Among the 319 studies in Depressive Disorder with a site in United States, this one is the 209th largest by planned enrollment of the 275 interventional ones that give a count, is one of 11 that started in 2026, is one of 49 in phase 2, reaches primary completion later than 39 of the 44 other live ones, and was the 319th registered.

Depressive Disorder

855 studies on the registry are indexed under Depressive Disorder; 159 are open to participants now.

Browse Depressive Disorder studies →

Open to participants now

39 of the 319 studies in Depressive Disorder with a site in United States are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 116 Depressive Disorder studies recruiting now, 44 (38%) set no upper age limit and 66 (57%) stop at 75 or younger; 24 take children under 18; 25 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 319 studies in Depressive Disorder with a site in United States, or all of them as a file.
02

Study summary

Dementia is one of the major causes of disability and among older adults globally, with 6.7 million Americans living with Alzheimer's disease. Depression is common in people with cognitive and memory problems.

Depression in the elderly increases the risk of disability, medical comorbidity, cognitive impairment, and death. Patients with depression are at an increased risk of worsening cognition. Further, patients with depression are traditionally excluded from therapeutic trials in Alzheimer's Disease and other dementias. Current medications to treat depression in patients with dementia haven't been helpful. Effective approaches to treating depression in dementia are necessary.

Ketamine has been studied extensively for the treatment of depression. It produces a rapid antidepressant effect with improvement of depressive symptoms reported 2 hours after infusion that continues for several days. Due to its rapid action, ketamine has gathered significant public attention. Providers in the community are already administering this drug to patients with dementia based on anecdotal evidence without evidence of its safety or benefit. A fast, safe, and effective treatment of depression may reduce the rate of cognitive decline in patients with dementia and reduce depression burden and improve quality of life and function. As patients with depression are likely unable to receive disease modifying therapies for Alzheimer's Disease (lecanemab or donanemab) rapid improvement of depressive symptoms with ketamine could represent treatment that allows them to be able to receive these therapies faster.

This proposal, will examine the safety, tolerability and feasibility of administering IV ketamine for the treatment of depression in participants with Alzheimer's Disease as well as obtain preliminary data regarding the treatment benefit.

Read the detailed description

Due to its rapid action, ketamine has gathered significant public attention. Providers in the community are already administering this drug to patients with dementia based on anecdotal evidence without evidence of its safety or benefit. A fast, safe, and effective treatment of depression may reduce the rate of cognitive decline in patients with dementia, but will also reduce neuropsychiatric symptom burden and improve quality of life and function. As patients with moderate to severe depression are likely unable to receive lecanemab or donanemab for treatment of AD, rapid improvement of depressive symptoms with ketamine could represent treatment that allows them to be able to receive disease-modifying therapies faster.

This proposed study will collect preliminary data on the safety, tolerability, and feasibility of administering IV ketamine for the treatment of depression in participants with MCI or mild dementia. It will also obtain preliminary data regarding the magnitude and duration of treatment benefit. If the hypothesis is validated, this project will support further studies including a multisite randomized double-blinded control trial examining ketamine as a novel treatment for depression in ADRD populations.

Primary Aim 1: To evaluate the feasibility, safety, tolerability, and acceptability of administering IV ketamine to participants with MCI or mild dementia due to AD.

Hypothesis 1: Ketamine administration will be acceptable, feasible, well tolerated, and safe as measured by 90% or greater completion rate, adverse events, change in vital signs, acceptability measures, and a Clinician Administered Dissociative States Scale (CADSS) score of \< 4 at 40 minutes post infusion.

Secondary Aim 2: To obtain preliminary evidence regarding the effects of ketamine on symptoms of depression in participants with MCI or mild dementia due to AD.

Hypothesis 1: Compared to the placebo control group, ketamine will lead to greater improvement in depression symptoms as determined by 50% or greater reduction in baseline Montgomery-Åsberg Depression Rating Scale (MADRS) score at 2 weeks (secondary outcome).

03

Conditions studied

  • Late Life Depression (LLD)
  • MCI
  • MCI-AD, Early Stage Alzheimer&#39;s Disease

Browse trials for

Keywords

  • Depressive disorder
  • Elderly
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age >= 60 years;
  2. Diagnosis for major depressive disorder meeting DSM5 criteria based on clinical assessment by the study clinician
  3. MADRS score >= 18
  4. Clinical diagnosis of MCI or mild dementia due to Alzheimer's Disease
  5. Quick Dementia Rating System (QDRS) 2-12
  6. (MoCA) > 14 at screening
  7. Positive AD biomarker (CSF p-tau181/Aβ42, tau/Aβ42, Aβ42/40, amyloid PET, Tau PET or clinical plasma assays such (p-tau 217 or 181), consistent with AD criteria
  8. Stable antidepressant medication regimen for at least 4 weeks prior to the start of infusions with plans to continue on the same medication and dose during the study
  9. Fluent in English
  10. Participants must have a study partner who is able to attend study visits and has regular contact with the participant, defined as approximately 5 or more hours per week, distributed across multiple days
  11. Currently be in active treatment with a Vanderbilt Behavioral Health (VBH) provider or community mental health provider. Care must remain continuous for the duration of ketamine treatment.

Exclusion criteria

Exclusion Criteria:

  1. Prior diagnosis of schizophrenia, bipolar disorder, or personality disorder that would interfere with safely participating in the trial
  2. Concomitant or past history of psychiatric or neurologic disorder other than those considered to be related to AD (e.g., head injury with loss of consciousness, symptomatic stroke, Parkinson's disease, severe carotid occlusive disease, , hemorrhagic and/or non-hemorrhagic stroke)
  3. Regular use of naltrexone or benzodiazepines
  4. History of , allergy, or intolerance of ketamine, midazolam, or clonidine
  5. Current use of memantine, unless the participant and their prescribing clinician agree to discontinue for the duration of the trial. Memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist, like ketamine, and is indicated for moderate to severe dementia - not for MCI or mild dementia as the participants enrolled in our trial. If applicable, memantine must be stopped for at least 4 weeks prior to the start of infusions, and participants must refrain from memantine use for the duration of the study
  6. Uncontrolled hypertension (systolic > 160mm HG or diastolic pressure > 90 mm HG)
  7. Unstable angina or recent (6 months) cardiovascular event (e.g., myocardial infarction)
  8. arrhythmias or other clinically significant abnormalities on at screening (minor abnormalities documented as clinically insignificant by the site PI are allowed)
  9. Any unstable and/or clinically significant medical condition likely to hamper the evaluation of safety and/or efficacy of study drug (e.g., moderate and/or severe untreated obstructive sleep apnea, stroke, or other cerebrovascular conditions, acute glaucoma), as per the site PI's judgement
  10. of \< 1 year because of terminal illness
  11. Alcohol or substance use disorder of moderate severity or greater in the last year
  12. Acute grief (\<1 month)
  13. Active suicidality or suicide attempt in 3 months prior
  14. Electroconvulsive therapy or transcranial magnetic stimulation in 2 months prior to enrollment
  15. Current or planned psychotherapy where the potential participant does not want to pause therapy until 2 weeks after the final infusion
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Ketamine

    Drug: Ketamine and saline

  • Placebo comparator
    Active Placebo (Midazolam)

    Drug: Active Placebo (Midazolam) Infusion

Interventions

  • DrugKetamine and saline

    Ketamine will be infused over 40 min twice weekly for two weeks. Ketamine will be calculated as 0.5mg/kg.

    Also known as: Ketamine (0.5 mg/kg)

  • DrugActive Placebo (Midazolam) Infusion

    Active placebo (midazolam) will be infused over 40 min twice weekly for two weeks. Active placebo (midazolam) dose will be calculated as 0.02mg/kg.

06

What researchers measure

Primary outcomes

  1. Feasibility of the Study as Measured by the Number of Participants Completing the Study

    Study feasibility will be evaluated by the number of participants who complete all required study visits and procedures through the final Week 8 visit. A greater number of participants completing all study requirements will indicate greater feasibility of the study procedures and participant retention.

    Time frame: From enrollment to the end of safety monitoring at 8 weeks

  2. Safety, as Measured by the Number of Participants with At Least One Treatment-Emergent Adverse Event

    The number of participants experiencing at least one treatment-emergent adverse event during the study will be recorded. Adverse events will be monitoring and documented through the study, including assessment of event severity and relationship to study intervention.

    Time frame: From the first medication infusion through study completion at 8 weeks

  3. Clinician-Administered Dissociative States Scale (CADSS) Total Score

    Dissociative symptoms will be assessed using the Clinician-Administered Dissociative States Scale (CADSS). Possible scores range from 0-92, with higher scores indicating greater severity of dissociative symptoms.

    Time frame: Week 1 Infusion 1, Week 1 Infusion 2, Week 2 Infusion 1, and Week 2 Infusion 2 prior to and 40 and 90 minutes after the start of each infusion.

  4. Severity of Suicidal Thoughts with Montgomery-Åsberg Depression Rating Scale (MADRS) Item 10 Score

    Suicidal thoughts will be assessed using Item 10 (Suicidal Thoughts) of the Montgomery-Åsberg Depression Rating Scale (MADRS). Scores range from 0 to 6, with higher scores indicating greater severity of suicidal thoughts.

    Time frame: From enrollment to the end of safety monitoring at 8 weeks

  5. Change in Severity of Suicidal Ideation as Measured by the Columbia-Suicide Severity Rating Scale (C-SSRS)

    Suicidal ideation will be assessed using the Columbia-Suicide Severity Rating Scale (C-SSRS). The highest level of suicidal ideation encorsed will be recorded using the C-SSRS severity categories ranging from 1 (wish to be dead) to 5 (suicidal intent with a specific plan). Change from baseline will be evaluated by comparing the highest level of suicidal ideation endorsed at follow-up assessments with the screening assessment. Higher scores indicate greater severity of suicidal ideation.

    Time frame: Screening (baseline), Week 1 Infusion 2, Week 2 Infusion 2

  6. Change in Suicidal Behavior as Measured by the Columbia-Suicide Severity Rating Scale (C-SSRS)

    Suicidal behavior will be assessed using the Columbia-Suicide Severity Rating Scale (C-SSRS). The presence of suicidal behavior, including actual, interrupted, or aborted suicide attempts and preparatory acts, will be recorded. Change from baseline will be evaluated by comparing the presence or absence of suicidal behavior at follow-up assessments with baseline. The number of participants reporting suicidal behavior will be summarized at each assessment.

    Time frame: Screening (baseline), Week 1 Infusion 2, Week 2 Infusion 2

  7. Number of Treatment-Emergent Side Effects as Measured by the Treatment-Emergent Symptom Scale (TESS)

    The Treatment-Emergent Symptom Scale (TESS) will be used to assess treatment-emergent side effects. The number of symptoms reported by participants will be recorded at summarized at each assessment.

    Time frame: Week 1 (Infusions 1 and 2), Week 2 (Infusions 1 and 2), Week 3, Week 4, and Week 8

  8. Severity of Treatment-Emergent Side Effects as Measured by the Treatment-Emergent Symptom Scale (TESS)

    The severity of treatment-emergent side effects reported by participants will be assessed using the Treatment-Emergent Symptoms Scale (TESS). Symptom severity ratings will be recorded and summarized at each assessment.

    Time frame: Week 1 (Infusions 1 and 2), Week 2 (Infusions 1 and 2), Week 3, Week 4, and Week 8

  9. Acceptability of the intervention as measured by the Acceptability of Intervention Measure (AIM)

    The Acceptability of Intervention Measure (AIM) is a 4-item self-report measure used to assess participants' perceptions of the acceptability of the intervention. Each item is rated on a 5-point Likert scale (1-5), with higher scores indicating a greater perceived acceptability of the intervention.

    Time frame: Week 4 (approximately 2 weeks after the final medication infusion)

Secondary outcomes

  1. Change in MADRS (Montgomery Asberg Depression Rating Scale) Score

    The MADRS total score range is 0-60, where higher scores indicate greater depression severity. 50% improvement in MADRS score is clinically meaningful and it is a standard used across depression trials to measure response to treatment.

    Time frame: Week 1 Infusion 2 and Week 2 Infusion 2

07

Study locations

1 site
  • Vanderbilt Psychiatric Hospital
    Nashville, Tennessee 37212, United States
    • Carrie Williams · Contact6159362162
    • Patricia Andrews, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — This study will include clinical and cognitive data from older depressed subjects. The final dataset will include clinical information about subject psychiatric diagnoses, psychiatric and medical history, cognitive data, and response to ketamine. The investigators will share data via the National Database for Clinical Trials related to Mental Illness (NDCT). NDCT provides a secure platform for data-sharing allowing for communication of research data, tools, and supporting documents. As required by NDCT, the investigators will obtain a Global Unique Identifier (GUID) for each participant. The investigators will additionally follow NDCT requirements to certify and review data, as well as timeline requirements for data submission and data sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will be shared according to policies from the NDCT and NDA (NIMH Data Archive). Descriptive data, outcome measures and analyzed data will be shared will be shared within 4 months of when a publication is accepted. Study data will be shared through the NDCT indefinitely

Access criteria: The NIH will provide access to scientific investigators for research purposes. Qualified researchers who have completed a Data Use Certification and received approval from the NDA Data Access Committee (DAC) may be approved to access broadly shared data. A separate request process exists for access to data in federated sources. Additionally, the DAC and support staff at NIH have access to NDA shared data.

Data sharing details ↗ · nda.nih.gov

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2029, 36 months later.

Of 43 phase 2 interventional studies under Depressive Disorder, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's planned 36 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2026
First posted
Nov 17, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Dec 2029
CompletionEst.
Dec 2029
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07943741
Responsible party
Patricia Andrews (Associate Professor of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center) — Principal investigator
First posted
Nov 17, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Dec 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Nov 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion